These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17692173)

  • 1. Point: active surveillance for favorable risk prostate cancer.
    Klotz L
    J Natl Compr Canc Netw; 2007 Aug; 5(7):693-8. PubMed ID: 17692173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?
    Klotz L
    Semin Radiat Oncol; 2008 Jan; 18(1):2-6. PubMed ID: 18082582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active surveillance for favorable risk prostate cancer: rationale, risks, and results.
    Klotz L
    Urol Oncol; 2007; 25(6):505-9. PubMed ID: 18047961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active surveillance for favorable-risk prostate cancer: who, how and why?
    Klotz L
    Nat Clin Pract Oncol; 2007 Dec; 4(12):692-8. PubMed ID: 18037873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining 'progression' and triggers for curative intervention during active surveillance.
    Klotz L
    Curr Opin Urol; 2015 May; 25(3):258-66. PubMed ID: 25714238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Bastian PJ; Carter BH; Bjartell A; Seitz M; Stanislaus P; Montorsi F; Stief CG; Schröder F
    Eur Urol; 2009 Jun; 55(6):1321-30. PubMed ID: 19286302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer.
    Klotz L
    J Urol; 2004 Nov; 172(5 Pt 2):S48-50; discussion S50-1. PubMed ID: 15535443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active Surveillance for Prostate Cancer: How to Do It Right.
    Garisto JD; Klotz L
    Oncology (Williston Park); 2017 May; 31(5):333-40, 345. PubMed ID: 28512731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
    Klotz L
    Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):204-9. PubMed ID: 23609043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
    Klotz LH; Nam RK
    Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active surveillance for low-risk prostate cancer.
    Klotz L
    Curr Opin Urol; 2017 May; 27(3):225-230. PubMed ID: 28267056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.
    Jo JK; Lee HS; Lee YI; Lee SE; Hong SK
    Asian J Androl; 2015; 17(2):248-52. PubMed ID: 25432498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer.
    Buethe DD; Pow-Sang J
    J Natl Compr Canc Netw; 2012 Sep; 10(9):1101-10. PubMed ID: 22956809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancer.
    Carter HB
    Curr Opin Urol; 2015 May; 25(3):277-82. PubMed ID: 25692722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.